Health
Biotechnology
Therapy

Amicus Therapeutics

$13.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-0.67%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FOLD and other stocks, options, ETFs, and crypto commission-free!

About

Amicus Therapeutics, Inc. engages in the discovery, developmen0t, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. Read More The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Employees
508
Headquarters
Cranbury, New Jersey
Founded
2002
Market Cap
2.55B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.54M
High Today
$13.63
Low Today
$13.17
Open Price
$13.46
Volume
1.15M
52 Week High
$17.62
52 Week Low
$8.27

Collections

Health
Biotechnology
Therapy
Technology
US
North America

News

Seeking Alpha15h

Amicus Therapeutics nabs two patents in U.S.; shares up 4% premarket

The USPTO has issued two new patents to Amicus Therapeutics (NASDAQ:FOLD) directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, to enhance uptake.

32
Associated Press15h

Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200

CRANBURY, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake.

3
Yahoo FinanceMar 15

Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT

Q4 2018 Amicus Therapeutics Inc Earnings Call Cranbury Mar 15, 2019 (Thomson StreetEvents) -- Edited Transcript of Amicus Therapeutics Inc earnings conference call or presentation Thursday, February 28, 2019 at 1:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Bradley L. Campbell Amicus Therapeutics, Inc. - President, COO & D...

12

Earnings

-$0.41
-$0.37
-$0.32
-$0.28
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.